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Background: Changes in management of COPD in primary care were studied following a training
exercise among Spanish general practitioners (GPs). The exercise involved dissemination of the
Spanish Society for Pulmonology and Thoracic Surgery (SEPAR) guidelines. The use of a portable
device to perform spirometry tests was evaluated to adequately categorize COPD and reduce
other diagnostic interventions.
Methods: A representative sample of GPs from general practices in Spain was recruited for the
study. In phase I, GPs performed an initial evaluation of 5 patients with COPD. In phase II, GPs
were randomly allocated to the following groups: 1) control group-G1 (GPs managing COPD ac-
cording to usual clinical practice); 2) training group-G2 (dissemination of SEPAR guidelines);
and 3) training group-G3 (dissemination of SEPAR guidelines and distribution of the Koko Peak
Pro to measure FEV1, FEV6, and FEV1/FEV6).
Results: Phase-I included 3254 physicians, who selected 16,024 patients. In phase II, 301 physicians
in G1, 1182 in G2, and 1141 in G3 selected 1481, 5798, and 5556 patients respectively. Evaluation of
the changes in COPD stratification according to the SEPAR guidelines showed that physicians in G1
adequately classified 60% of patients, compared to 69% in G2 and 88.5% in G3 (p< 0.0001). On
comparing groups G1 and G3, a significant reduction was seen in chest X-rays (from 42% to 32%,
pZ 0.0002) and arterial blood gas studies performed (from 34% to 22%, p< 0.0001).umologia, Institut del To`rax, Hospital Clı´nic, IDIBAPS, Universitat de Barcelona, Villarroel 170, 08036e
; fax: þ34 204852789.
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68 N. Soler et al.Conclusions: Thedissemination of the SEPAR guidelines and the utilization of the portable device for
spirometry may improve management of COPD in primary care.
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3,254 physicians 
16,024 patients
630 physicians excluded
TRAINING SESSIONIntroduction
Chronic obstructive pulmonary disease (COPD) is one of the
main causes of morbidity and mortality in the industrialized
world.1 The global incidence of this disease in Spain is 9.1%
among the population aged between 40 and70 years; it is
the 5th most common cause of death in men.2,3 In Spain, the
disease accounts for 15% and 40% of all consultations in the
primary care setting and respiratory medicine depart-
ments, respectively, and is responsible for between 35%
and 40% of all permanent occupational disabilities.4
Despite the important health care impact of COPD in the
general population, different European studies have
revealed shortcomings in terms of diagnosis, severity strat-
ification and treatment of patients with this disease.5e7
Primary care spirometry is a uniquely valuable tool in
the evaluation of patients with respiratory symptoms, as it
allows general practitioners (GPs) to diagnose or rule out
COPD and to correctly stage patients, since spirometric
tests facilitate early diagnosis of asthma and COPD.8e11
Recently, several studies have shown the need to improve
diagnosis of COPD in primary care, supporting the useful-
ness of office spirometry and the optimization of joint
strategies within the different health care levels in order to
improve diagnosis and management of the disease.7,12e15
Similarly, increasing evidence indicates that forced
expiratory volume in six seconds (FEV6) can be used as
a valid alternative to forced vital capacity (FVC) and is an
easier test for patients to perform in the primary care
setting.16e18
We hypothesized that primary diagnosis of COPD and
adequate management of COPD patients in primary care
would change after an accurate training exercise based on
the application of the Spanish Society for Pulmonology and
Thoracic Surgery (SEPAR) guidelines3 and the introduction
of office spirometry, especially for symptomatic cases with
unsuspected airflow obstruction. The a priori outcomes
established were improved diagnosis, severity classifica-
tion, and management of COPD patients in primary care.
Furthermore, the use of a portable device for easy-to-
perform spirometric tests to measure FEV1 and FEV6 was
evaluated for its effect on adherence to these guidelines
and, thus, adequate categorization of COPD and a reduc-
tion in other diagnostic interventions.G1
301 physicians
1,481 patients
G2
1,182 physicians
5,798 patients
G3
1,141 physicians
5,556 patients
PHASE II
2,624 physicians
Figure 1 EMMEPOC study: flow chart of inclusion.Patients and methods
Study design and population
The EMMEPOC study is an observational, descriptive,
multicenter project performed in Spanish general prac-
tices. Data was collected from October 2004 to December
2005. The participating general practitioners (GPs) workingin primary care centers in 40 populations in Spain were
recruited from a practice database of the sponsoring
companies.
Ethics committee approval
The study was conducted in compliance with ethics
committee regulations, and the local institutional boards
approved the clinical protocol. All the subjects who met the
study inclusion criteria were informed about the study in the
presence of a witness, after which oral consent was
obtained.
Inclusion criteria
A representative sample of a Spanish GPs from general
practices in both rural and urban populations was recruited
for the study. The target population consisted of subjects
over 35 years of age, with diagnosed COPD or current
smokers with suspected COPD, who agreed to participate in
the study. In order to obtain a representative sample of
patients, each participating GP selected the 5 first patients
with COPD or suspected COPD in their general practice.
The EMMEPOC study included 3254 GPs (baseline group),
who selected a total of 16,024 patients with suspected or
confirmed COPD. A total of 2624 GPs were randomized to 1
of 3 groups (the ratio of randomization was 1 for control
group to 4 for intervention groups): 1) control group (G1)
consisted of GPs dealing with COPD according to their usual
clinical practice and who did not receive a training session;
2) training group (G2) involved intervention by dissemina-
tion of the SEPAR guidelines among the participating GPs;
and 3) training group þ portable device for spirometry (G3)
consisted of dissemination of the SEPAR guidelines and
distribution of the portable spirometer (Fig. 1).
Changes in the management of COPD in primary care 69In patients included in group G3, spirometry testing was
performed using a portable electronic device (Koko Peak
Pro 6, software-KAMP Professional version 2.2.27 2001
PDSI, Ferraris Respiratory, Louisville, CO, USA). The system
is a simple and easy-to-use non-calibrating device that can
be useful for monitoring and assessing the severity of
obstructive pulmonary diseases.
Classification of the severity of COPD was based on the
FEV1 value (expressed as a percentage of the reference
value) recorded from the data obtained from the medical
history of the selected patients. COPD classification,
according to the recommendations of SEPAReSEMYC,3 was
as follows:
- Mild COPD: FEV1 60e80% of theoretical (reference or
predicted) value
- Moderate COPD: FEV1 40e59% of theoretical value
- Severe COPD: FEV1< 40% of theoretical valueTable 1 Distribution of the population of General Practi-
tioners (GPs) analyzed.
GPs, n(%) Patients, n(%)
Phase I Phase II Phase I Phase II
G1 281 (11.4) 301 (11.5) 1,365 (11.4) 1,481 (11.5)
G2 1,112 (45.0) 1,182 (45.0) 5,395 (45.2) 5,798 (45.2)
G3 1,080 (43.6) 1,141 (43.5) 5,178 (43.4) 5,556 (43.3)
Total 2,473 (100) 2,624 (100) 11,940 (100) 12,835 (100)
GPZ general pratitioners; G1Z control group; G2Z training
group; G3Z training groupþ Koko Peak Pro.Training session
The information from GPs was collected prospectively using
a specific questionnaire. All GPs completed a Case Report
Data (CRD) form specifically designed for this study. After
completing the CRD form, including demographic and
occupational information on the participating GPs and the
characteristics of their consulting office, physicians were
questioned about diagnosis, treatment and prevention of
COPD. The baseline FEV1 value was obtained from the
previous data collected in the clinical records of each
patient.
After the inclusion period, the GPs in groups G2 and G3
were scheduled for a training session based on the literal
transcription of the SEPAReSEMYC guidelines the diagnosis,
severity stratification and management of COPD. These
training sessions were performed by pulmonologists from
Spanish hospital institutions who had received previous
information about the SEPAR guidelines. Additionally, the
GPs from group G3 attended a spirometry training session
on the KoKo Peak Pro device immediately after the SEPAR
guidelines presentation. Forced expiratory manoeuvres
were repeated until 3 acceptable and reproducible tests
were obtained. The best FEV1 and FEV6 values were
recorded and the FEV1/FEV6 ratio was calculated according
to the recommendations of the National Lung Health
Education Program for the detection of COPD in the primary
care setting.19 Standardized spirometric measurements and
reference values were obtained using a common European
protocol defined previously by Roca et al.20
The complete clinical data of the selected patients were
taken from the clinical records. A month-and-a-half after
the conclusion of the training session, each GP selected the
first 5 patients with COPD or suspected COPD seen
consecutively in their respective offices. Collection of the
clinical data CRD was completed within a 3-month period.
Statistical analysis
Quantitative data are expressed as mean SD and quali-
tative data are shown as percentages. In all the statisticaltests, normal distribution of both the quantitative and
qualitative variables was assumed, in view of the large size
of the sample divided into 3 groups (>3000 GPs). Baseline
2 2 homogeneity testing was performed among the 3
intervention groups (G1, G2, and G3), based on analysis of
variance (ANOVA) for the quantitative variables, and
logistic regression for the qualitative variables. The Pearson
correlation coefficient (r) was used to compare the histor-
ical measure of FEV1% with that of the corresponding values
of FEV1% and FEV6%, determined by the Koko Peak Pro.
The changes in the 3 groups were assessed by analysis of
covariance (ANCOVA), fitting the baseline value for the
quantitative variables, and using logistic regression, also
with baseline fitting, for the qualitative variables, where
applicable. All tests were 2-tailed, and statistical signifi-
cance was considered at p< 0.05. The SAS version 8.2.
statistical packages for Microsoft Windows was used
throughout.
Results
Population characteristics
Phase I included 3254 GPs, who selected a total of 16,024
patients with suspected or confirmed COPD. A total of 630
(19%) physicians declined to participate and were
excluded; the remaining GPs were randomized to one of 3
groups: control group (G1), comprised 301 GPs who
selected 1481 patients; training group (G2), comprised 1182
GPs who selected 5798 patients; and trainingþ Koko Peak
Pro group (G3), comprised 1141 GPs who selected 5556
patients (Table 1). The demographic and occupational data
of the GPs participating in the study, and the characteris-
tics of the consulting offices in which primary care was
provided are shown in Tables 2 and 3. No statistically
significant differences were found among the 3 study
groups as the populations were homogeneous for the
described demographic and occupational characteristics.
With respect to the spirometric tests carried out, 40% of the
GPs reported having performed an average of 1.4 0.9 in
the previous year; no differences were observed among the
3 groups.
Primary diagnosis
Twenty-five percent of the patients selected were current
smokers (ex-smokers, 75%). The respiratory symptoms most
Table 2 Demographic data of the General Practitioners (GPs) included in the study.
G1 G2 G3 Total
Working life (years)
N 278 1,083 1,056 2,417
M SDa 19.7 6.4 19.0 6.8 18.8 6.8 18.8 6.8
Gender
N 278 1,092 1,066 2,436
Males, n (%) 210 (75.5) 723 (66.2) 728 (68.3) 1.661 (67.1)
Females, n (%) 68 (24.4) 369 (33.8) 338 (31.7) 775 (32.9)
Type of centreb
N 275 1,067 1,032 2,374
Rural, n (%) 93 (33.8) 267 (25.0) 298 (28.9) 658 (26.8)
Peri-urban, n (%) 27 (9.8) 166 (15.6) 144 (14.0) 337 (14.5)
Urban, n (%) 155 (56.4) 634 (14.0) 590 (57.2) 1.379 (58.8)
Allocated populationc
N 276 1,092 1,063 2,431
<1500, n (%) 52 (18.8) 172 (15.6) 172 (18.2) 417 (15.9)
1500e2000, n (%) 122 (44.2) 537 (49.2) 514 (48.4) 1.173 (49.7)
2000e2500, n (%) 77 (27.9) 265 (24.3) 239 (22.5) 581 (23.6)
>2500, n (%) 25 (9.1) 118 (10.8) 117 (11.0) 260 (10.8)
G1Z control group; G2Z training group; G2Z training groupþ Koko Peak Pro.
a Data shown as mean SD.
b Setting of the primary care center.
c population allocated to the consulting office.
70 N. Soler et al.frequently recorded in the CRD were exertional dyspnoea in
84% of cases, cough in 89%, and expectoration or increased
sputum volume in 76%. No differences were found between
the cohort of patients selected in phase I and phase II
regarding smoking history and respiratory symptoms.
However, we found statistical differences among the study
groups regarding the primary diagnosis characteristics cor-
responding to the patients included before (phase I) and after
(phase II) the training session provided for theGPs. Before theTable 3 Characteristics of the consulting offices of the particip
G1
Phase I Phase II
Exclusive dedication
nursing care
N 269 178
n (%) 162 (60.2) 102 (57.3)
Centers with spirometer
N 272 179
n (%) 147 (54.0) 102 (57.0)
Training in spirometry
N 266 174
n (%) 109 (52.4) 95 (53.4)
Reference centre
N 274 175
Hospital, n (%) 147 (53.7) 95 (54.3)
Specialized centre, n (%) 122 (44.5) 73 (41.7)
Data are expressed as percentage of total.
G1Z control group; G2Z training group; G3Z training group þ spiro
Phase IZ before training session; Phase IIZ after training session.training session, a diagnosis of COPD was recorded in 78% of
cases in G1, 82.8% in G2, and 80.1% in G3; no between-group
differences were observed. However, after the training
session, significant differences were observed in the inter-
vention groups G2 andG3with respect to primary diagnosis of
COPD (82.8% in phase I vs 80.1% in phase II in G2 [pZ 0.0005]
and 80.1% in phase I vs 76.6% in phase II in G3 [p< 0.0001]) or
suspected COPD (9.4% in phase I vs 11.8% in phase II in G2
[pZ 0.032] and 9.6% in phase I vs 13.6% in phase II in G3ating GPs.
G2 G3
Phase I Phase II Phase I Phase II
1,070 671 1,051 743
722 (67.5) 393 (58.6) 645 (61.4) 365 (49.1)
1,069 676 1,054 759
582 (54.4) 391 (57.9) 515 (48.9) 355 (46.8)
1,044 662 1,045 750
529 (50.1) 333 (50.3) 483 (46.2) 327 (43.6)
1,058 726 1,037 767
495 (46.8) 321 (42.5) 476 (45.9) 351 (45.8)
543 (51.3) 409 (54.1) 546 (52.7) 394 (51.4)
metry.
Changes in the management of COPD in primary care 71[p< 0.0001]) (Table 4). Of particular relevance is the fact
that after the training session, a significant reduction was
observed in the percentage of arterial blood gas studies (43%
vs 36% in G2 [p< 0.0001] and 40% vs 22% in G3 [p< 0.0001])
and chest X-rays (78% vs 75% in G2 [p< 0.0001] and 77% vs 71%
in G3 [p< 0.0001]) requested as initial diagnostic explora-
tions (Table 5). In addition, application of the SEPAReSEMYC
guidelines and measurement of FEV1% using the Koko Peak
Pro among the GPs in the G3 group reduced the number of
follow-up spirometry tests performed (36% vs 32%,
p< 0.001); no such differences were observed in the other 2
groups. The results relating to the Koko Peak Pro were
documented in 821 patients, with a mean FEV1% of
57.5 16.3, a mean FEV6% of 72.6 19.9, and a mean FEV1/
FEV6% ratio of 70.8 17.8. Table 6 shows data on the airflow
obstruction classifications made. Similarly, a good correla-
tionwas observed between themean FEV1% value reported in
the clinical history and FEV1% determined using theKoko Peak
Pro (54.3 16,2 vs 57.5 1.3; rZ 0.79; p< 0.0001), and
between FEV1/FVC% and FEV1/FEV6% ratios (69.2 17.6 vs
70.8 17.8; rZ 0.72; p< 0.0001), although this correlation
was stronger in cases of moderate to severe airflow
obstruction. After the changes in COPD severity stratification
according to the SEPAReSEMYC guidelines in phase II were
evaluated, the GPs in the G1 group adequately classified 60%
of the patients, compared to 69% and 88.5% in groups G2 and
G3, respectively (Table 7).
Differences in treatment regimen
The distribution of drugs prescribed according to the severity
of COPD before and after the training session is shown in
Tables 8 and 9. In cases of mild COPD, all 3 groups showed
a clear increase in the use of anticholinergic drugs, although
this difference was statistically significant in patients in all
groups (56.3% vs 68.1% in G1 [p< 0.001]; 54.8% vs 76.1 in G2
[p< 0.001]; and52.8% vs 77.8% in G3 [p< 0.0001]). Similarly,
a considerable reduction was observed in the use of theoph-
ylline and oral and inhaled corticosteroids. SimilarTable 4 Differences among the study groups regarding the prim
G1 G2
Phase I
NZ 1,338
Phase II
NZ 1,432
p-value Phase I
NZ 5,268
Ph
NZ
COPD
n (%) 1,044 (78.0) 1,112 (77.7) 0.801 4,362 (82.8) 4,5
Bronchial asthma
n (%) 188 (14.9) 212 (14.8) 0.545 584 (11.9)
Suspected COPD
n (%) 148 (11.6) 140 (9.8) 0.275 493 (9.4) 5
Othersa
n (%) 26 (1.9) 21 (1.5) 0.323 96 (1.8)
Data are expressed as absolute numbers and percentage of total.
G1Z control group; G2Z training group; G3Z training groupþ Koko
Comparations are made between GPs included in each study group b
a Other chronic pulmonary diseases.differences were observed in cases of moderate to severe
COPD, with a clear rise in anticholinergic drug prescription
(74% vs 90% in G2 [p< 0.0001] and 72% vs 88% in G3
[p< 0.0001]), and a decrease in inhaled corticosteroid use
(28% vs 25% inG2 [pZ 0.01] and 27% vs 22% inG3 [pZ 0.003]).
Discussion
The clinical relevance of this study can be summarized as
follows: (1) Dissemination of the SEPAReSMYC guidelines
within a single training session for Spanish GPs influenced
the diagnosis of patients with COPD and improved clinical
decisions; (2) The use of the portable spirometric device for
measuring FEV1, FEV6 and FEV1/FEV6, improved the severity
stratification and pharmacological treatment of COPD
patients in primary care.
The diagnosis and management of COPD require a study
of respiratory function to demonstrate persistent airflow
obstruction and assess its severity. Case history and chest
x-rays may be useful for establishing the differential diag-
nosis with other disorders that may manifest similar
symptoms. The results of a study recently conducted in
Spain including 6758 subjects over 40 years of age show that
only 60% of individuals with chronic respiratory symptoms
had consulted a physician and only 45% had undergone
spirometry.6 The EMMEPOC study, which involved 3254 GPs
working in 40 populations in Spain, found that application
of the SEPAR recommendations 3 for the care of COPD
patients, together with FEV6 and FEV1/FEV6 determination
using a portable spirometric device, allowed accurate
diagnosis and classification of up to 88.5% of patients. It is
noteworthy that, following the training session, the GPs in
G3 requested fewer arterial blood gas and chest x-ray
studies as initial diagnostic tests.
A relevant issue in the accurate diagnosis of COPD in
primary care is the percentage of false positives observed,
in which the diagnosis of COPD is assumed on the basis of
spirometry data. Bendarek et al found a significant
decrease in over-diagnosis when office spirometry wasary patient diagnosis reported in the case report data (CRD).
G3
ase II
5,624
p-value Phase I
NZ 5,064
Phase II
NZ 5,468
p-value
60 (80.1) 0.0005 4,055 (80.1) 4,190 (76.6) <0.0001
664 (1.8) 0.251 691 (13.7) 621 (11.4) 0.0003
98 (11.8) 0.032 485 (9.6) 745 (13.6) <0.0001
95 (1.9) 0.582 82 (1.6) 76 (1.4) 0.340
Peak Pro
efore and after training session.
Table 5 Comparison among the groups regarding the number of spirometric studies, blood gas tests and chest X-rays made.
G1 G2 G3
Phase I Phase II p Phase I Phase II p Phase I Phase II p
Forced spirometry
N 1,365 1,481 5,397 5,798 5,178 5,556
n (%) 631 618 0.619 2,299 2,464 0.0015 2,028 1,756 <0.0001
(42.6) (41.7) (40.2) (43.1) (36.5) (31.6)
Blood gases
N 1,054 1,118 3,981 4,315 3,725 4,336
n (%) 429 380 0.009 1,718 1,543 <0.0001 1,505 936
(40.7) (34.0) (43.1) (35.8) (40.4) (21.6) <0.0001
Chest X-rays
N 1,011 1,056 3,954 4,295 3,634 3,309
n (%) 753 788 0.941 3,088 3,112 0.0005 2,800 2,350 <0.0001
(74.5) (74.6) (78.1) (74.8) (77.1) (71.0)
All comparisons between G1 and groups G2 and G3 are significant (p< 0.0001).
G1Z control group; G2Z training group; G3Z training groupþ Koko Peak Pro.
Phase IZ before the training session; Phase IIZ after the training session.
Table 7 Adequate COPD classification according to S
Spanish Society of Pulmonology (SEPAR) guidelines.
G1 G2 G3
Phase I
Patients
selected, N
1,365 5,394 5,178
Patients
adequately
classified, n
(%)
837
(61.3)
3.275
(60.7)
3,016
(58.3)
72 N. Soler et al.used; this suggests that the application of good quality
testing in primary care may have a positive impact on the
management of COPD.7 Although epidemiological screening
was not an objective of our study, we found significant
differences regarding the primary diagnosis of COPD
between the control group (G1) of GPs who received no
training and the intervention groups (G2 and G3).
Many clinical practice guidelines that focus specifically
on the diagnosis and management of COPD have been
published over the last 10 years. However, the impact of
the application of these guidelines and their effectiveness
has not been verified.21,22 We found that a single training
session for GPs, based ondissemination of the SEPARe
SEMYC guidelines, appears to improve primary diagnosis of
COPD and significantly change the severity stratification
accordingly.
An interesting finding of our study was that the use of
a portable monitor for FEV1% and FEV6% measurements
proved to be very effective for classifying patients
according to the degree of airflow obstruction. Vande-
voorde et al.23 calculated the values of FEV1/FEV6 and FEV6
that would best match an FEV1/FVC of 0.70 of predicted
values, and they found FEV1/FEV6 and FEV6 suitable for
screening purposes in primary care. These data established
cutoffs for the detection of obstructive spirometricTable 6 Koko peak pro -monitor data group G3: airflow
obstruction severity classification.a
Mild nZ 365 Moderate
nZ 343
Severe nZ 113
FEV1% 65.8 15.1 52.3 11.7 41.5 12.5
FEV6% 76.7 18.2 70.1 20,0 63,6 20.2
FEV1/FEV6% 66.8 14.1 57.4 18.1 48.3 19.4
G3Z training groupþ Koko Peak Pro.
a Data are expressed as median  standard deviation and as
a percentage of reference values.patterns and were consistent with previous studies stress-
ing the importance of spirometry in primary care, using
portable airflow monitoring devices.17,23e25
Despite the fact that the KoKo Peak Pro 6 spirometer
used was not validated to the spirometer standards of
either the American Thoracic Society or the European
Thoracic Society,26 it provides an easily reproducible test
and involves measures such as PEF, FEV1% and FEV6%, which
are simple to interpret in general practice. We observed
a good correlation between the mean FEV1% values repor-
ted by the patients’ clinical histories and FEV1% determinedPhase II
Patients
selected, N
1,481 2,119 5,556
Patients
adequately
Classified, n
(%)
890
(60.1)
3,998
(69.0)
4,917
(88.5)
p-value 0.469 <0.0001 <0.0001
All comparations are made between patients selected by each
study group before and after training session.
Phase I: before training session; Phase II: after training session.
Note that the patients selected are different in every phase of
the study
Table 8 Treatment regimens in the patients classified as mild COPD.a
G1 G2 G3
Fixed combination
Anticholinergicþ short-
action beta-2-agonistb
Phase I 13.9 9.2 8.40
Phase II 10.0 5.8 5.00
p 0.005 <0.0001 <0.0001
Long-action beta-2-
agonistcþ corticoid
Phase I 31.0 28.8 26.8
Phase II 29.0 28.5 25.3
p 0.41 0.67 0.07
Bronchodilators
Short-action beta-2-
agonist
Phase I 42.4 45.8 44.7
Phase II 36.5 38.4 38.1
p <0.0001 <0.0001 <0.0001
Long-action beta-2-
agonist
Phase I 15.2 19.7 17.7
Present II 36.5 17.2 17.0
p 0.02 <0.0001 0.24
Anticholinergic agentsd Phase I 56.3 54.8 52.8
Phase II 68.1 76.1 77.8
p <0.0001 <0.0001 <0.0001
Theophylline Phase I 10.5 7.7 6.9
Phase II 5.5 7.6 4.9
p 0.0002 0.0002 <0.0001
Corticoids
Oral Phase I 3.10 4.00 3.40
Phase II 3.50 2.90 2.30
p 0.8084 0.0243 0.0031
Inhaled Phase I 20.40 17.60 17.70
Phase II 16.10 12.40 13.60
p 0.04 <0.0001 <0.0001
Antibiotics
Phase I 5.0 5.9 5.7
Phase II 3.9 6.1 4.5
p 0.41 0.79 0.04
a Data are expressed as percentage of total.
b Short-action beta-2-agonist (salbutamol, terbutaline).
c Long-action beta-2-agonists (salmeterol, formoterol).
d Anticholinergic agents (tiotropium, ipratropium bromide). Phase I: before training session; Phase II: after training sessionþ SEPAR-
SemFYC recommendations. G1Z control group; G2Z training group; G2Z training groupþ Koko Peak Pro.
Changes in the management of COPD in primary care 73using the Koko Peak Pro (rZ 0.79; p< 0.0001), and
between the FEV1/FVC% and FEV1/FEV6% ratios (rZ 0.71,
p< 0.001), respectively. In agreement with our data, Han-
sen and colleagues reported that FEV1/FEV6 correctly
identifies moderate to severe obstruction, but is less reli-
able for detecting mild airflow obstruction.27
Moreover, the results of our study provide information
on changes in the pharmacological management of COPD
patients seen in primary care. Under-diagnosis and under-
treatment are considered to be major problems in the
management of COPD. Under-treatment could be reduced
by confirming a definitive diagnosis using spirometry, in
accordance with national or international guidelines, and,
consequently, prescribing appropriate medication.28
Firstly, it was found that more than half of the patients
with COPD or suspected COPD received at least 1 drug inthe context of their management scheme, similar to other
studies.4,29,30 The most frequently prescribed drugs were
anticholinergic agents, followed by inhaled short-action
beta-2-agonists. Of note was the scarce use of combined
therapy with inhaled corticosteroids and inhaled long-
action beta-2-agonists. However, although there were no
important differences in the regimens used, a clear
increase in the prescription of anticholinergic agents was
noted, reaching 78%, together with a considerable reduc-
tion in the use of theophyllines, oral corticosteroids and, to
a lesser extent, inhaled corticosteroids. Since the lack of an
accurate diagnosis may limit evaluation of the treatment
administered to patients with COPD, it may be more
appropriate to compare the prescription habits observed in
our study with those reported by other studies in which the
diagnosis is definitive.18,31 Thus, in previous European
Table 9 Treatment regimens in the patients classified moderate to severe COPD.a
G1 G2 G3
Fixed combination
Anticholinergicþ short-
action beta-2-agonist
Phase I 7.9 10.8 13.3
Phase II 6.6 6.0 9.4
p 0.32 <0.0001 0.0001
Long-action beta-2-
agonistþ corticoid
Phase I 48.0 48.8 46.0
Phase II 50.0 52.3 51.2
p 0.55 0.06 0.004
Bronchodilators
Short-action beta-2-
agonistb
Phase I 58.3 58.5 58.0
Phase II 50.7 52.3 56.0
p 0.001 <0.0001 0.26
Long-action beta-2-
agonistc
Phase I 28.8 26.6 22.3
Phase II 27.9 22.9 20.2
p 0.82 0.02 0.21
Anticholinergicd Previous 70.5 74.0 72.1
Present 82.4 86.9 87.8
p 0.004 <0.0001 <0.0001
Theophylline Phase I 28.8 30.0 24.2
Phase II 28.7 24.6 21.8
p 1.00 <0.0001 0.03
Corticoids
Oral Phase I 29.5 22.8 22.1
Phase II 30.1 20.8 24.1
p 1.00 0.19 0.009
Inhaled Phase I 31.7 28.3 27.4
Phase II 25.7 24.6 22.8
p 0.004 0.009 0.003
Antibiotics
Phase I 13.7 14.7 13.8
Phase II 19.9 11.1 14.2
p 0.13 0.02 0.61
G1Z control group; G2Z training group; G2Z training groupþ Koko Peak Pro.
a Data expressed with percentage of total.
b Short-action beta-2-agonist (salbutamol, terbutaline).
c Long-action beta-2-agonists (salmeterol, formoterol).
d Anticholinergic agents (tiotropium, ipratropium bromide). Phase I: before training session; Phase II: after training sessionþ SEPAR-
SemFYC recommendations.
74 N. Soler et al.studies including patients with confirmed COPD, a similar
therapeutic profile was observed: inhaled beta-2-agonists
in 60e70% of cases, anticholinergic drugs in 40e82% of
cases, inhaled corticosteroids in up to 60% of cases, and
theophyllines in 10e20% of cases.32e35 Our results reflect
the usual heterogeneity of the drugs commonly prescribed
for COPD in primary care, indicating a change in the ther-
apeutic profile, with increased use of anticholinergic agents
as first line treatment and fewer inhaled corticosteroids,
particularly in cases of mild or moderate disease.36
We conclude that it is possible to improve the diagnosis
and management of COPD patients after a training program
aimed at GPs working in general practices in Spain. There
was an additional improvement when the GPs who received
the training incorporated a portable spirometric device formonitoring lung function. However, we feel that diagnosis,
severity stratification and management of COPD in the
primary care setting require an additional effort that should
include encouraging the use of the recommended medical
guidelines, extensive training of GPs in current practice on
performing spirometric tests, and optimization of coordi-
nation among the different levels of health care.Acknowledgement
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